Table 2. Uni- and multivariate Proportional Hazard Cox Regression of prognostic markers for mortality.

	UnadjustedHazard Ratio(95% CI)	P-value	AdjustedHazard ratio(95% CI)	P-value
Serum 25-OHD >30 ng/ml	Ref. Value	–	Ref. Value	–
Serum 25-OHD 20–30 ng/ml	0.84(0.63–1.12)	0.234	0.90(0.67–1.21)	0.48
Serum 25-OHD <20 ng/ml	1.03(0.79–1.33)	0.83	1.11(0.85–1.46)	0.45
Age pr. Year above age 50 *	1.04(1.03–1.06)	<0.001	1.05(1.03–1.06)	<0.001
Charlsonscore >3	1.53(1.11–2.11)	0.009	1.49(1.06−2.09)	0.019
Neutrophils **	1.05(1.02–1.09)	0.004	1.05(1.02–1.09)	<0.001
Severe COPD ***	1.48(1.13–1.93)	0.004	1.41(1.06–1.86)	0.017
Very Severe COPD ***	1.97(1.45–2.67)	<0.001	2.19(1.58–3.02)	<0.001
Azithromycin Vs. Placebo	1.03(0.84–1.27)	0.75	0.97(0.78–1.20)	0.76
BMI <20	1.18(0.91–1.53)	0.20	1.30(0.99–1.70)	0.05
Pack years >40 years	1.17(0.95–1.42)	0.14	1.27(1.02–1.70)	0.034

^*Estimated hazard ratio associated with an increment of one year.

^**Estimated hazard ratio associated with an increment of 1 * 10⁹ cells/L.

^{&ast;&ast;&ast;}Moderate COPD (79–50 FEV1% predicted), Severe COPD (30–50 FEV1% predicted) [28] and Very Severe COPD (<30 FEV1% predicted).